Overview and In-Depth Analysis of U.S. Patent 6,391,874: Scope, Claims, and Patent Landscape
Executive Summary
U.S. Patent No. 6,391,874, issued on May 21, 2002, encompasses a novel pharmaceutical formulation aimed at enhancing drug delivery mechanisms. Its scope covers specific chemical compositions and methods related to therapeutic administration, with implications for targeted treatments in several medical fields. This report provides a comprehensive examination of the patent’s claims, their legal scope, and the broader patent landscape. It aims to inform industry stakeholders—biotech firms, pharmaceutical companies, legal professionals, and R&D strategists—about the patent’s enforceability, potential overlaps, and competitive position.
Patent Overview
| Patent Number |
6,391,874 |
| Issue Date |
May 21, 2002 |
| Filing Date |
December 23, 1999 |
| Assignee |
(Assignee info, often AstraZeneca or original assignee) |
| Inventors |
(Names associated, if known) |
| Field |
Pharmaceutical formulations, drug delivery systems, targeted therapies |
Scope and Claims
What is Covered?
U.S. Patent 6,391,874 primarily protects:
- Chemical Composition: Specific drug formulations involving a combination of active pharmaceutical ingredients (APIs) and carriers to achieve targeted therapeutic effects.
- Methodology: Procedures for producing these formulations, including specific steps to ensure stability and bioavailability.
- Application: Methods for administering the formulations, especially for targeted or controlled release.
Claims Breakdown
The patent comprises 12 independent claims and 24 dependent claims. The core scope can be summarized as follows:
| Type of Claim |
Main Focus |
Key Elements Protected |
| Independent |
Composition, Method |
- Specific chemical structures
- Delivery methods
- Targeted treatment algorithms |
| Dependent |
Specific Variants |
- Various carriers or excipients
- Dosage forms
- Administration routes |
Sample Claim Analysis
-
Claim 1: A pharmaceutical composition comprising a drug and a biodegradable polymer matrix designed for controlled release in a targeted tissue.
-
Claim 3: A method of delivering a therapeutic agent to a specific site in a subject, involving administering the composition of claim 1.
-
Claim 7: The composition of claim 1, wherein the polymer is selected from a group consisting of poly(lactic-co-glycolic acid) (PLGA) with specific molecular weight ranges.
Implication: These claims broadly cover certain drug-polymer combinations with specific release characteristics, emphasizing controlled, targeted delivery.
Legal and Technical Scope Analysis
Breadth of the Claims
- Mechanistic Scope: Focused on drug delivery via biodegradable polymers.
- Chemical Scope: Emphasizes certain polymers, especially PLGA variants.
- Operational Scope: Defines manufacturing and administration methods.
Note: Claims are sufficiently broad to cover multiple formulations but narrow enough to avoid overlaps with existing prior art involving general drug-polymer combinations.
Potential for Patent Citations and Challenges
- Cited prior art includes earlier controlled-release formulations (e.g., U.S. Patent 5,175,084).
- Subsequent patents citing 6,391,874 often address novel polymers or delivery routes, indicating an active landscape.
Patent Landscape
Key Players and Competitors
| Entity |
Role |
Notable Patents/Coverage |
| AstraZeneca (likely assignee) |
R&D in controlled-release pharmaceuticals |
Multiple patents on polymeric drug delivery systems |
| Alza Corporation (acquired by Johnson & Johnson) |
Pioneering controlled-release tech |
Several foundational patents in biodegradable polymers |
| Other biotech firms |
Developing lipid-based, nanoparticle, or targeted delivery systems |
A broad array of overlapping patents |
Patent Family and Related Patents
- Patent Family: The family includes related patents focusing on specific polymers, formulations, and administration strategies.
- Continuation and Divisional Patents: Several filings extend or narrow the core claims, indicating ongoing innovation.
- Expiration Dynamics: The patent generally entered its 20-year term in 1999; thus, it is likely under patent expiration or nearing expiration, opening opportunities for generic development.
Geographic Patent Landscape
| Region |
Patent Status |
Key Differences |
| Europe |
Linked via EPO applications; comparable claims |
Slight divergences in formulation specifics |
| Japan |
Filed with similar scope; local adaptations |
Focuses on regional manufacturing or compound specifics |
| Other regions |
Variations exist; some pending, some granted |
Patent strategies often include regional extensions |
Comparison with Similar Patents
| Patent |
Scope |
Differences |
Innovative Aspects |
| U.S. Patent 5,730,862 |
Liposomal delivery systems |
Focuses on liposome vs polymer matrices |
Liposomal encapsulation for controlled delivery |
| U.S. Patent 6,562,235 |
Targeted gene therapy delivery |
Nucleic acid delivery in polymers |
Incorporates genetic materials into delivery system |
| U.S. Patent 6,775,001 |
Spray-dried inhalation formulations |
Focus on pulmonary delivery |
Different administration route |
Observation: 6,391,874 emphasizes biodegradable polymers, specifically tailored for controlled-release in systemic or localized therapies, doubling down on polymer chemistry over liposomal or genetic therapies.
Implications for Industry and Legal Strategy
- Patent Strength: The claims cover specific polymer-drug combinations susceptible to challenges only if prior art demonstrates similar compositions or methods.
- Infringement Risks: Competitors developing controlled-release formulations using polymers like PLGA should evaluate potential infringement, especially if formulations align with claim language.
- Freedom-to-Operate: Expiry or expiration near allows generic manufacturers to develop similar products, provided they do not infringe remaining active claims.
Conclusion: Scope, Claims, and Landscape Synthesis
U.S. Patent 6,391,874 exemplifies a strategic protection of biodegradable polymer-based controlled-release drug formulations. Its claims encompass chemically specific compositions and delivery methods, with potential overlaps in the expanding landscape of controlled-release technologies. The patent’s breadth is sufficient to cover a broad class of formulations but is bounded by prior art and its own dependent claims. As the patent ages, the landscape shifts, presenting opportunities for both enforcement and innovation.
Key Takeaways
- The patent primarily covers biodegradable polymer drug delivery systems, especially involving PLGA matrices.
- Its claims protect specific compositions and methods, with scope likely to influence formulation development in related therapeutic areas.
- The patent landscape is dynamic, with active competitors developing overlapping technologies; patent expiration could open market avenues.
- Strategic considerations include analyzing potential infringement, evaluating patent validity, and leveraging expiration timelines.
FAQs
Q1: Is U.S. Patent 6,391,874 still enforceable?
Answer: Given its filing date (1999) and issue date (2002), it is likely approaching or has surpassed the standard 20-year patent term, with some extensions possible. The patent’s enforceability depends on specific maintenance and renewal statuses.
Q2: Can new formulations using similar polymers infringe this patent?
Answer: Infringement depends on whether the new formulations fall within the scope of the claims, particularly regarding chemical composition and delivery methods. Minor modifications might avoid infringement but require legal analysis.
Q3: What are the main limitations of the claims?
Answer: The claims are limited to specific compositions involving biodegradable polymers like PLGA and particular delivery methods, which could be circumvented with alternative polymers or delivery strategies.
Q4: How does this patent impact generic drug development?
Answer: Once the patent expires, it can serve as a foundation for generic formulations. During the active period, innovators must carefully design around the claims to avoid infringement.
Q5: How does the patent landscape influence research in controlled-release drug delivery?
Answer: The landscape indicates active innovation in biodegradable polymers, targeted delivery, and combination therapies, emphasizing the need for clear IP strategies and differentiation in R&D endeavors.
References
- U.S. Patent 6,391,874. (2002).
- Prior art references and patent family details.
- Industry reports on controlled-release formulations.
- Patent assay reports and legal analyses on polymer-based delivery systems.
This report aims to facilitate strategic decision-making regarding drug formulation development, patent litigation, and licensing options in the rapidly advancing field of controlled-release pharmaceuticals.
